Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Transthyretin Stabilizers
  • 1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
  • 1.2.4 RNAi Therapy
  • 1.2.5 Others
• 1.3 Market by Application
  • 1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
  • 1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
• 2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
  • 2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
  • 2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
• 2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
  • 2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
  • 2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
  • 2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
  • 2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
  • 3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
  • 3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
• 3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
• 3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
  • 3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
• 3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
• 3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
• 3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type

• 4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
• 4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)

5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application

• 5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
• 5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
• 6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
  • 6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
  • 6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
  • 6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
• 6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
  • 6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
  • 6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
  • 6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
• 6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
  • 6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
  • 6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.3 Canada

7 Europe

• 7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
• 7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
  • 7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
  • 7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
  • 7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
• 7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
  • 7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
  • 7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
  • 7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
• 7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
  • 7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
  • 7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
• 8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
  • 8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
  • 8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
  • 8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
• 9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
  • 9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
  • 9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
  • 9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
• 9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
  • 9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
  • 9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
  • 9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
• 9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
  • 9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
  • 9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
• 10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
  • 10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
  • 10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
  • 10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Pfizer Inc
  • 11.1.1 Pfizer Inc Company Details
  • 11.1.2 Pfizer Inc Business Overview
  • 11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.1.5 Pfizer Inc Recent Development
• 11.2 GlaxoSmithKline Plc
  • 11.2.1 GlaxoSmithKline Plc Company Details
  • 11.2.2 GlaxoSmithKline Plc Business Overview
  • 11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.2.5 GlaxoSmithKline Plc Recent Development
• 11.3 Eidos Therapeutics
  • 11.3.1 Eidos Therapeutics Company Details
  • 11.3.2 Eidos Therapeutics Business Overview
  • 11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.3.5 Eidos Therapeutics Recent Development
• 11.4 Ionis Pharmaceuticals, Inc
  • 11.4.1 Ionis Pharmaceuticals, Inc Company Details
  • 11.4.2 Ionis Pharmaceuticals, Inc Business Overview
  • 11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.4.5 Ionis Pharmaceuticals, Inc Recent Development
• 11.5 Alnylam Pharmaceuticals
  • 11.5.1 Alnylam Pharmaceuticals Company Details
  • 11.5.2 Alnylam Pharmaceuticals Business Overview
  • 11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.5.5 Alnylam Pharmaceuticals Recent Development
• 11.6 Prothena Corporation Plc
  • 11.6.1 Prothena Corporation Plc Company Details
  • 11.6.2 Prothena Corporation Plc Business Overview
  • 11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.6.5 Prothena Corporation Plc Recent Development
• 11.7 Intellia Therapeutics, Inc
  • 11.7.1 Intellia Therapeutics, Inc Company Details
  • 11.7.2 Intellia Therapeutics, Inc Business Overview
  • 11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.7.5 Intellia Therapeutics, Inc Recent Development
• 11.8 Corino Therapeutics, Inc
  • 11.8.1 Corino Therapeutics, Inc Company Details
  • 11.8.2 Corino Therapeutics, Inc Business Overview
  • 11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
  • 11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
  • 11.8.5 Corino Therapeutics, Inc Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer